<--- Back to Details
First PageDocument Content
Antiandrogens / Chemistry / Clinical medicine / Enzyme inhibitors / Cancer / Prostate cancer / Organofluorides / Galeterone / Steroids / Enzalutamide / Abiraterone acetate / Medivation
Date: 2016-08-03 18:48:38
Antiandrogens
Chemistry
Clinical medicine
Enzyme inhibitors
Cancer
Prostate cancer
Organofluorides
Galeterone
Steroids
Enzalutamide
Abiraterone acetate
Medivation

Microsoft WordDOCX

Add to Reading List

Source URL: securities.stanford.edu

Download Document from Source Website

File Size: 234,17 KB

Share Document on Facebook

Similar Documents

Antiandrogens / Chemistry / Clinical medicine / Enzyme inhibitors / Cancer / Prostate cancer / Organofluorides / Galeterone / Steroids / Enzalutamide / Abiraterone acetate / Medivation

Microsoft WordDOCX

DocID: 1rnqZ - View Document

Health / Cancer / Chemistry / National Institutes of Health / Medivation / Enzalutamide / Medical research / Astellas Pharma / Prostate cancer / Pharmaceutical industry / Food and Drug Administration / BayhDole Act

PDF Document

DocID: 1qonz - View Document

Astellas Pharma / Nikkei 225 / Antiandrogens / Tacrolimus / Enzalutamide / OSI Pharmaceuticals / Regadenoson / Wholesaling / Erlotinib / AmerisourceBergen / Pharmaceutical industry in China / Cardinal Health

Authorized Distributors of Record Below is a listing of the Authorized Distributors of Record (ADRs) for Astellas Pharma US, Inc. and OSI Pharmaceuticals, LLC, in accordance with 21 C.F.R. § d). If you have quest

DocID: 1pHnS - View Document

Antiandrogens / Prostate cancer / Organofluorides / Nitriles / Medivation / Progonadotropins / Enzalutamide / Astellas Pharma / Abiraterone acetate / Docetaxel / Pharmaceutical industry / Medicare Part D

    January 14, 2016    The Honorable Sylvia Mary Mathews Burwell   Secretary 

DocID: 1oJy5 - View Document

Prostate cancer / Abiraterone / Melanoma / Docetaxel / Vemurafenib / Metastasis / Eastern Cooperative Oncology Group / Medicine / Chemistry / Organofluorides

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Vemurafenib, Abiraterone, Enzalutamide) Part 1 - Patient Information

DocID: 1gjh0 - View Document